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Platelets act as the first line of defense after vascular injury and play a key role in the prevention of excessive blood loss 
through the formation of a thrombus at the site of vessel damage. 
Unwanted, excessive platelet activation and hyper-reactive plate-
lets are thought to contribute to atherothrombosis that can lead to 
myocardial infarction and stroke. Several pathological conditions 
such as hyperlipidemia,1,2 type 2 diabetes mellitus,3,4 metabolic 
syndrome,5 obesity,5,6 and high cholesterol7–12 have been related 
to platelet hyper-reactivity and increased platelet responses.
Formation of procoagulant platelets is one way in which 
platelets can be classed as hyper-reactive. A subclass of proco-
agulant platelets are coated platelets (previously called COAT 
platelets)13 that expose and retain high levels of phosphatidyl-
serine and high levels of α-granule proteins on their surface 
including factor V, fibrinogen, fibronectin, and von Willebrand 
factor.14–16 Coated platelets are also associated with deregu-
lated levels of intracellular calcium, depolarized mitochondrial 
membranes, generation of reactive oxygen species (ROS), loss 
of membrane integrity, and the release of platelet micropar-
ticles.17–19 Coated platelets are reported to support coagula-
tion reactions, whereas cleavage and inactivation of proteins 
required for integrin signaling prevents aggregation and inhibits 
traditional platelet activation in response to platelet agonists.20,21
Several intracellular nuclear receptors that have been iden-
tified in human platelets such as the liver X receptor (LXR) 
and farnesoid X receptor (FXR), are recognized for their roles 
in the transcriptional regulation of metabolic pathways that 
are disrupted in conditions such as type II diabetes mellitus, 
metabolic syndrome, and hyperlipidemia.22–27 The LXR recep-
tors are involved in the regulation of cholesterol homeostasis 
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and their natural ligands, for example, oxysterols, are cho-
lesterol derivatives.28–33 Cholesterol derivatives have been 
found to deregulate platelet responses to several platelet ago-
nists, with some derivatives potentiating and others inhibiting 
aggregation.34–36 Similarly, the FXR receptor is activated by 
bile acids and other cholesterol derivatives with roles in the 
regulation of bile acid and cholesterol homeostasis37–39 and 
has also been shown to play a role in insulin homeostasis.40,41 
Bile acids have previously been associated with platelet dys-
function42 and treatment of platelets with bile acids has been 
shown to be associated with membrane vesiculation and plate-
let swelling.43,44
Increasing evidence supports nongenomic actions for 
intracellular nuclear receptors, including FXR and LXR, 
that are clearly distinct from their well-established genomic 
roles.27,45,46 Previous work has shown that ligands for both 
LXR and FXR inhibit platelet activation by GPVI (glyco-
protein VI) agonists and thrombin, as evidenced by inhibi-
tion of platelet aggregation, granule secretion, and calcium 
mobilization in response to collagen receptor GPVI agonists 
and thrombin. Furthermore outside-in signaling through inte-
grin αIIbβ3 is inhibited resulting in a significant reduction 
in thrombus formation and stability in vivo,25,27 although the 
mechanisms by which these ligands cause this inhibition seem 
to be different.25,27
The ability of LXR and FXR ligands to inhibit platelet 
function seems at odds with the observations that conditions 
associated with increased circulating levels of LXR or FXR 
ligands, such as hyperlipidemia, type 2 diabetes mellitus, met-
abolic syndrome, obesity, and high cholesterol are associated 
with increased platelet reactivity and an increased risk of car-
diovascular disease.1–12 Furthermore, many natural and syn-
thetic LXR and FXR ligands including hydroxycholesterols 
and bile acids have been shown to be cytotoxic and proapo-
potic in some cell types.47–53 We have also previously observed 
that platelets treated with high concentrations of FXR ligand 
GW4064 showed decreased sample turbidity indicative of 
platelet swelling and procoagulant activity.27 Therefore, 
despite previous observations that treatment of platelets with 
LXR or FXR ligands inhibits platelet function to platelet ago-
nists, understanding how these nuclear receptor ligands non-
genomically affect platelets before agonist stimulation is of 
clear importance.
It has been previously described that during thrombus 
formation 2 distinct populations of platelets appear, coaggre-
gated platelets, which support thrombus growth, and loosely 
attached platelets that expose phosphatidylserine, which sup-
port coagulation but cannot support platelet activation.20,54 We 
set out to determine whether LXR and FXR ligands can both 
activate and inhibit platelets.
In this study, we sought to explore in more detail how 
LXR and FXR ligands may affect the ability of platelets to 
respond to platelet agonists. We identify that treatment of 
platelets with LXR or FXR ligands can convert platelets to 
a procoagulant state that is consistent with coated platelet 
formation.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
LXR and FXR Ligands Increase 
Procoagulant Activity of Platelets
We set out to determine whether treatment with the LXR 
or FXR ligands (using concentrations previously shown to 
inhibit platelet function) was able to convert resting platelets 
to the procoagulant state. To do this, several markers of pro-
coagulant activity were measured, including phosphatidylser-
ine exposure, microparticle formation, platelet swelling, and 
loss of membrane integrity. Phosphatidylserine exposure was 
determined by measuring annexin V binding after treatment of 
washed platelets with either the LXR ligand GW3965 or FXR 
ligand GW4064 (1, 5, 10, and 20 µmol/L) for 10 minutes. 
Platelets treated with either GW3965 or GW4064 showed 
a concentration-dependent increase in phosphatidylserine 
exposure with increases in the median fluorescence intensity 
(Figure 1Ai) and percentage of positive cells (Figure 1Aii) for 
annexin V binding observed (gating strategy shown in Figure 
IA in the online-only Data Supplement). Microparticle forma-
tion from washed platelets (Figure 1B) was also increased in 
a concentration-dependent manner in GW3965- or GW4064-
treated platelets in comparison to vehicle-treated controls 
(gating strategy shown in Figure IB through ID in the online-
only Data Supplement). Platelet swelling (Figure 1C and 1D), 
measured as a decrease in sample turbidity and an increase of 
mean platelet volume (using an ACT5 hematology analyzer) 
was also evident after treatment with either the LXR or FXR 
ligands (5, 10, 20, and 40 µmol/L). The observed decrease in 
sample turbidity was not because of aggregation as it could 
not be prevented by pretreatment with integrilin (5 µmol/L, a 
concentration shown to block fibrinogen binding and aggrega-
tion), and cell lysis was excluded as treatment with GW3965 
or GW4064 did not reduce platelet count (Figure II in the 
online-only Data Supplement).20 Finally, membrane integ-
rity (Figure 1E) determined by measuring calcein permeabil-
ity was also altered after treatment with either GW3965 or 
GW4064. Both compounds caused a decrease in calcein fluo-
rescence, indicating that the integrity of the platelet membrane 
had been compromised, as has been previously observed dur-
ing procoagulant platelet formation.21,55,56 In support of these 
observations being the result of specific activity of the LXR 
and FXR receptors, concentration-dependent increases in 
annexin V binding were also observed after treatment with nat-
ural ligands for the LXR receptor 27-hydroxycholesterol and 
24S-hydroxycholesterol (10, 30, and 100 µmol/L) or natural 
ligand for the FXR receptor chenodeoxycholic acid (100 and 
300 µmol/L; Figure III in the online-only Data Supplement).
Nonstandard Abbreviations and Acronyms
FXR farnesoid X receptor
GPVI glycoprotein VI
LXR liver X receptor
ROS reactive oxygen species
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LXR and FXR Ligands Initiate 
Formation of Coated Platelets
Coated platelets are procoagulant platelets that in addi-
tion to exposure of phosphatidylserine are characterized by 
high levels of surface retention and exposure of α-granule 
proteins including factor V, fibrinogen, fibronectin, and 
von Willebrand factor. To determine whether GW3965 and 
GW4064 were capable of stimulating coated platelet for-
mation, fibrinogen binding, and P-selectin exposure were 
measured after treatment with either ligand. Washed plate-
lets treated with either the LXR or FXR ligand (1, 5, 10, and 
20 µmol/L) exhibited a concentration-dependent increase in 
fibrinogen binding and P-selectin exposure in comparison 
to vehicle-treated controls (Figure 2A and 2B). Because no 
exogenous fibrinogen was added to the assay, we hypothesize 
that the fibrinogen bound at the platelet surface comes from 
the activated platelet via α-granule secretion, which also 
leads to increased P-selectin exposure at the platelet surface. 
As with annexin V binding, treatment of platelets with the 
natural ligands for the LXR and FXR receptors, 27-hydroxy-
cholesterol and 24S-hydroxycholesterol (10, 30, and 100 
µmol/L) or chenodeoxycholic acid (100 and 300 µmol/L) also 
caused an increase in fibrinogen binding, further supporting 
that these observations are because of specific activity of the 
LXR and FXR receptors (Figure III in the online-only Data 
Supplement).
In further support of procoagulant coated platelet forma-
tion, immunofluorescence microscopy of platelets stained 
Figure 1. Liver X receptor (LXR) and farnesoid X receptor (FXR) ligands induce platelet procoagulant activity. Human washed platelets 
were treated for 10 min with or without increasing concentrations of GW3965 (1, 5, 10, 20, and 40 µmol/L) or GW4064 (1, 5, 10, 20, and 
40 µmol/L) or vehicle control before analysis by flow cytometry for (A) annexin V binding, which is a measure of phosphatidylserine expo-
sure, and data expressed as (i) median fluorescence intensity and (ii) percentage of annexin V–positive cells; (B) formation of micropar-
ticles, determined by gating for the microvesicle population using forward and side scatter profiles of ApogeeMix beads. Data expressed 
as number of phosphatidylserine (PS)–positive events per microliter. C and D, Platelet swelling, measured by analyzing (C) light transmis-
sion, with an increase in transmission associated with increased platelet swelling (i) and (ii) representative traces and (iii) representative 
images. D, (i) data expressed as % of light transmission; (ii) mean platelet volume. E, Calcein fluorescence, to measure membrane integ-
rity, expressed as median fluorescence intensity. Results are mean+SEM for n≥3. *P<0.05 in comparison to vehicle controls.
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with annexin V and an antifibrinogen antibody confirmed 
the formation of phosphatidylserine exposing ballooned 
platelets that bind fibrinogen after treatment with GW3965 
(20 µmol/L) and GW4064 (20 µmol/L) in comparison to 
vehicle-treated controls (Figure 2Ci). In further support 
of this, imaging flow cytometry confirmed that GW3965- 
and GW4064-treated platelets show an increase in fibrino-
gen and annexin V binding compared with vehicle-treated 
control (Figure IV in the online-only Data Supplement), 
and single cell flow cytometry 2 feature dot plot analysis 
showed that platelets found to be positive for annexin V 
binding were also found to bind fibrinogen. This is shown 
in Figure 2Cii, with an increased number of events observed 
in the upper right quadrant of the dot plot after treatment 
with GW3965 or GW4064 compared with vehicle control 
(Figure 2Cii).
Figure 2. Liver X receptor (LXR) and farnesoid X receptor (FXR) agonists initiate coated platelet formation. Human washed platelets were 
treated with increasing concentrations of GW3965 (1, 5, 10, and 20 µmol/L), GW4064 (1, 5, 10, and 20 µmol/L), or vehicle control and 
tested for several different markers of coated platelet formation including (A) fibrinogen binding, (B) α-granule components, measured by 
detecting P-selectin exposure, (D) serine protease activity, measured by quantification of release of fluorescence as a result of conversion 
of Z-Gly-Gly-Arg-AMC fluorescent substrate for 1 h at 37°C, and (E) bound fibrin. Data expressed as median fluorescence intensity. C, 
Human platelets treated with GW3965 (20 µmol/L), GW4064 (20 µmol/L), or vehicle were stained with annexin V–Cy5 (in red) and antifi-
brinogen (Alexa 488 conjugated; in green) and analyzed by (i) fluorescence microscopy on a ×100 oil immersion lens and (ii) flow cytom-
etry. (i) Representative images and (ii) representative scatter plots shown. Other results are mean+SEM for n≥3. *P<0.05 in comparison to 
vehicle controls.
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Increases in platelet prothrombinase activity and the sub-
sequent conversion of fibrinogen into fibrin is another key 
feature of coated procoagulant platelets.57 The ability of the 
LXR and FXR agonists to induce platelet prothrombinase 
activity was quantified as the rate of cleavage of Z-Gly-Gly-
Arg-AMC, a serine protease substrate. Both GW3965- and 
GW4064-treated platelets showed a significant increase in 
serine protease activity in comparison to vehicle controls 
(Figure 2D). Although this is likely to reflect assembly of 
the prothrombinase complex at the cell surface, the action 
of other coagulation enzymes may also contribute. In sup-
port of this increase in serine protease activity being because 
of increased thrombin activity, a dose-dependent increase in 
surface fibrin, detected using an antifibrin antibody, was also 
observed after treatment with either GW3965 or GW4064 
(Figure 2E). Additionally, analysis of thrombin generation 
in platelet-rich plasma by calibrated automated thrombogra-
phy found that treatment with either GW3965 or GW4064 
reduced the time taken to reach peak thrombin generation 
compared with vehicle-treated controls (Figure V in the 
online-only Data Supplement). Together, these observations 
support a role for both LXR and FXR ligands in the regula-
tion of platelet prothrombinase (serine protease) activity and 
fibrin generation.
LXR and FXR Ligand-Dependent 
Formation of Procoagulant Platelets 
Inhibits Activation of Integrin αIIbβ3
It has been shown that fibrinogen binding to coated plate-
lets is independent of activation of integrin αIIbβ3.16,20 
We, therefore, tested whether the observed increase in 
fibrinogen binding in GW3965- or GW4064-treated plate-
lets was associated with activation of integrin αIIbβ3. In 
support of integrin αIIbβ3 not being activated, neither 
GW3965 nor GW4064 caused an increase in PAC-1 anti-
body binding to the open (active) conformation of integrin 
αIIbβ3 (Figure 3A). Furthermore, pretreatment of plate-
lets with integrilin at a concentration (5 µmol/L) known to 
block fibrinogen binding to integrin αIIbβ327 was unable 
to reverse the observed increase in fibrinogen binding 
(Figure 3B). These results suggest that increased binding 
of fibrinogen to the platelet surface is independent of inte-
grin αIIbβ3 activation as has been previously described for 
coated platelet formation.16,20
Phosphatidylserine exposure in coated platelets is 
associated with closure and inhibition of the αIIbβ3 inte-
grin and other platelet receptors.20 Interestingly, previously 
published data have shown that treatment with similar con-
centrations of GW3965 and GW4064 causes inhibition of 
platelet aggregation to GPVI agonists and thrombin.25,27 In 
further support of these findings, we observed inhibition of 
integrin αIIbβ3 function, determined by measuring PAC-1 
binding, after treatment with GW3965 and GW4064 (10 and 
20 µmol/L) and stimulation with collagen-related peptide 
(CRP-XL; 1 µg/mL) or thrombin (0.1 U/mL; Figure VIA in 
the online-only Data Supplement). Treatment with GW3965 
and GW4064 also resulted in reduced cell adhesion and 
spreading on fibrinogen-coated coverslips (Figure VIB and 
VIC in the online-only Data Supplement). In support of the 
formation of coated platelets after treatment with GW3965 
and GW4064 leading to inhibition of integrin αIIbβ3, dot 
plot analysis of CRP-stimulated (1 µg/mL) and thrombin-
stimulated (0.1 U/mL) platelets shows an increase in phos-
phatidylserine exposure and a reduction in PAC-1 binding 
after treatment with GW3965 or GW4064 compared with 
vehicle controls. In particular, platelets identified as posi-
tive for annexin V binding were found to be negative for 
PAC-1 binding, as shown by lack of events in the upper right 
quadrant of the dot plot (Figure 3C). Analysis of nonadhered 
platelets after exposure to fibrinogen-coated coverslips 
for 45 minutes also showed that GW3965- and GW4064-
treated platelets displayed significantly increased levels of 
annexin V binding in the nonadhered platelets (which is 
associated with inhibition of adhesion and spreading) com-
pared with vehicle control (Figure VID in the online-only 
Data Supplement). Finally, we tested whether the observed 
increase in fibrinogen binding in GW3965- or GW4064-
treated platelets was associated with Talin cleavage, a cal-
cium-dependent step in the activation of integrin αIIbβ3. As 
shown in Figure VIE in the online-only Data Supplement, 
platelets treated with GW3965 (20 µmol/L) or GW4064 (20 
µmol/L) did not show cleavage of the Talin head domain 
compared with an ionomycin-treated (5 µmol/L) positive 
control, further suggesting that integrin αIIbβ3 is not acti-
vated, leaving αIIbβ3 unable to initiate outside-in signaling.
GW3965- and GW4064-Induced Platelet 
Procoagulant Activity Is Associated With 
Depolarization of the Mitochondrial 
Membrane and Is Dependent on Sustained 
Increases in Intracellular Calcium
Phospholipid scrambling and conversion to the procoagulant 
state in platelets is attributed to both loss of mitochondrial 
transmembrane potential and an increase in intracellular cal-
cium.19,55 To test whether this was the underlying mechanism 
behind the observed characteristics of procoagulant plate-
lets induced by the LXR and FXR ligands, the integrity of 
the mitochondrial membrane was investigated using the JC-1 
fluorophore. As shown in Figure 4A in comparison to vehicle 
control, both GW3965 and GW4064 cause a significant reduc-
tion in the JC-1 FL2/FL1 ratio, indicating mitochondrial mem-
brane depolarization. It has also been previously described 
that cyclophilin D can play a role in formation of procoagulant 
platelets after stimulation by platelet agonists.19 Treatment of 
platelets with cyclosporine A, a cyclophilin D inhibitor, pre-
vented FXR ligand GW4064-mediated increases in annexin 
V binding similar to that observed in thrombin- and CRP-
stimulated platelets, but phosphatidylserine exposure after 
treatment with LXR ligand GW3965 was unaffected similar 
to that observed after treatment with ionomycin (Figure 4B). 
Thereby identifying a role for cyclophilin D in FXR agonist 
but not in LXR agonist mediated increases in platelet proco-
agulant activity.
Single platelet analysis of calcium signaling, looking at 
immobilized individual platelets under arterial shear flow rates 
(20 dyn/cm2 that is equivalent to 1000 s−1) identified that when 
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treating platelets with vehicle control, spikes of calcium sig-
naling (intermittent pulses of fluorescence) are observed that 
are likely to be because of the shear forces the platelets experi-
ence under flow.58 In contrast, when flowing either GW3965 
or GW4064 over the platelets, single platelet calcium signal-
ing was increased and sustained compared with the signaling 
observed in the presence of vehicle control (Figure 4C and 
4D). This increased and sustained signaling is then seen to 
dissipate over time, which appears to be because of the com-
promised integrity of the platelet membrane and leakage of 
the calcium dye from the platelet.
Having identified alterations in calcium signaling after 
treatment with either LXR or FXR ligands, we set out to 
determine whether the observed formation of coated plate-
lets was dependent on intracellular or extracellular calcium. 
Platelets were treated with either GW3965 or GW4064 or 
vehicle in the presence or absence of BAPTA-AM (10 µmol/L) 
to chelate intracellular calcium (but leaving extracellular cal-
cium levels unaffected) or EGTA (1 mmol/L), which chelates 
extracellular calcium. Treatment of platelets with BAPTA-AM 
prevented the GW3965- and GW4064-induced increases in 
annexin V binding and fibrinogen binding even after treatment 
with high concentrations of either ligand, suggesting that the 
observed phosphatidylserine exposure is dependent on intra-
cellular calcium (Figure 4E). In contrast, treatment of platelets 
with EGTA did not prevent GW3965- and GW4064-induced 
Figure 3. Liver X receptor (LXR) and farnesoid X receptor (FXR) agonists inhibit αIIbβ3. Human washed platelets were prepared, and the 
effect of GW3965 or GW4064 (10 and 20 µmol/L) on (A) integrin αIIbβ3 activation determined by PAC-1 antibody binding and (B) fibrino-
gen binding in the presence or absence of integrillin (5 µmol/L), an inhibitor of integrin αIIbβ3 fibrinogen binding. (Data expressed as 
median fluorescence intensity, mean+SEM for n≥3. C, PAC-1 binding and phosphatidylserine exposure in CRP-stimulated (1 µg/mL) and 
thrombin-stimulated (0.1 U/mL) platelets was determined. Representative scatter plots shown.
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Figure 4. Mitochondrial transmembrane potential and sustained calcium signaling are required for the induction of LXR- and FXR-medi-
ated procoagulant activity. Human washed platelets were treated for 10 min with or without increasing concentrations of GW3965 (1, 5, 
10, and 20 µmol/L) or GW4064 (1, 5, 10, and 20 µmol/L) or vehicle control before analysis by flow cytometry for (A) changes in the mito-
chondrial membrane potential, determined by using JC-1 dye and expressing the results using the FL2/FL1 ratio. An increase in the ratio 
compared with control indicates hyperpolarization of the mitochondrial membrane, whereas a decrease in the FL2/FL1 ratio indicates 
membrane depolarization. B, Platelets were treated for 10 min with or without increasing concentrations of GW3965 (10 and 20 µmol/L) 
or GW4064 (10 and 20 µmol/L) or vehicle control in the presence of cyclosporine A (5 µmol/L), a cyclophilin D inhibitor, before analysis 
by flow cytometry for annexin V binding. Data expressed as percentage of annexin V–positive events. Thrombin-treated (0.1 U/mL)/CRP-
treated (1 µg/mL) and ionomycin-treated (5 µmol/L) samples were included as positive controls. C and D, Ca2+ imaging in single platelets 
under flow. Human washed platelets loaded with Fluo4-AM (2 µmol/L) were attached onto mouse antihuman PECAM-1 antibody–coated 
(WM59) glass-bottom Vena8 GCS biochips (Cellix Ltd, Dublin, Ireland) and vehicle. C, GW3965 (20 µmol/L) or (D) GW4064 (20 µmol/L) 
were then flowed through the chips at a slow shear rate of 400 s−1 and calcium signaling monitored by observing fluorescence for 5 min. 
Single platelet, representative calcium signaling trace shown. E and F, Platelets were treated with GW3965 or GW4064 (0, 10, and 20 
µmol/L) in the presence or absence of (E) BAPTA (10 µmol/L) or (F) EGTA (1 mmol/L) before analysis by flow cytometry for (E) annexin V 
binding, and fibrinogen binding and (F) fibrinogen binding and P-selectin exposure. Thr (0.1 U/mL) and Thr (0.1 U/mL)+CRP (5 µg/mL) 
included as positive controls for fibrinogen binding in the presence of EGTA. Data expressed as median fluorescence intensity. Results are 
mean+SEM for n≥3 and expressed as percentage of vehicle control. *P<0.05 in comparison to vehicle controls.
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increases in fibrinogen binding or P-selectin exposure (annexin 
V binding not monitored, as annexin V requires presence of 
Ca2+ in the buffer to bind phosphatidylserine), suggesting that 
LXR and FXR ligand-induced formation of coated platelets is 
not dependent on extracellular calcium (Figure 4F).
GW3965 and GW4064 Do Not 
Activate Apoptotic Pathways
In other cell types, FXR and LXR agonists have been shown to 
cause cytotoxicity and initiation of apoptosis.47–53 As several of 
the observed changes induced by GW3965 and GW4064, such 
as phosphatidylserine exposure and depolarization of the mito-
chondrial membrane potential, are also observed during cellular 
apoptosis, the effects of GW3965 and GW4064 on cytochrome 
c release and caspase activation were determined. As shown in 
Figure 5, neither was capable of causing the cytosolic release of 
cytochrome c (a key stage before caspase activation that occurs 
in apoptosis) or caspase cleavage, in contrast to ABT-263 (10–
20 µmol/L), an initiator of apoptosis. This was confirmed by 
incubation of platelets with a caspase inhibitor Z-FAD-FMK 
(10 µmol/L) before treatment with GW3965 or GW4064 as 
Z-FAD-FMK was unable to reverse the potentiation of annexin 
V binding (Figure 5C), suggesting the observations described 
here are because of conversion of platelets to the procoagulant 
state and not a result of initiation of cellular apoptosis.
LXR and FXR Ligand-Induced Procoagulant 
Activity Is Dependent on Reactive Oxygen Species
The generation of reactive oxygen species (ROS) is associ-
ated with and dependent on coated platelet formation.18,19 To 
Figure 5. Liver X receptor (LXR) and farnesoid X receptor (FXR) ligands do not initiate apoptosis. A and B, Human washed platelets were 
pretreated with GW3965 or GW4064 (10 and 20 mmol/L) or ABT-263 (10 and 20 mmol/L; initiator of apoptosis) for 2 h before (A) lysis in 
mitochondria isolation lysis buffer. The heavy mitochondrial membrane was then isolated from its releasate by centrifugation, and the 
presence of cytochrome C in the mitochondrial releasate determined by Western blotting. B, Activation and cleavage of caspases was 
also determined in GW3965-treated or GW4064-treated (10 and 20 µmol/L) platelet lysates by Western blotting for the cleaved activated 
form of the caspases ABT-263 (20 mmol/L) treated platelets were included as a positive control for initation of apoptosis. C, Annexin V 
binding was determined in (i) GW3965-treated and (ii) GW4064-treated platelets after pretreatment with a caspase inhibitor Z-FAD-FMK 
(10 mmol/L). Representative blots are shown, and results are mean+SEM for n=3 and expressed as fold increase compared with control. 
*P<0.05 in comparison to vehicle controls.
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determine whether the mode of action of the LXR and FXR 
ligands in converting platelets to coated platelets involves 
ROS generation, the ability of GW3965 and GW4064 to ini-
tiate formation of ROS was determined using the fluorescent 
dye H2DCFDA. Small increases in H2DCFDA fluorescence 
and ROS generation were observed after treatment with 
either GW3965 or GW4064 (20 µmol/L; Figure 6A). It has 
previously been described that antioxidants can prevent Thr/
CRP-mediated formation of coated platelets,18 and in sup-
port of a role for ROS in GW3965- and GW4064-mediated 
increases in procoagulant coated platelet formation, we 
found that phosphatidylserine exposure and fibrinogen bind-
ing were significantly attenuated in the presence of a ROS 
scavenger n,n′-diphenyl-p-phenylenediamine (Figure 6B and 
6C). These data suggest an important role for ROS in LXR 
and FXR ligand-dependent coated platelet formation. Given 
the involvement of ROS but not components of the platelet 
apoptotic pathways, this suggests that platelets are converted 
to the procoagulant state via a pathway similar to necrosis, as 
described previously.55
Discussion
Here, we describe that both LXR and FXR receptor ligands 
are capable of converting platelets to the procoagulant state 
at micromolar concentrations that cause inhibition of plate-
let activity and show receptor specificity in knockout mouse 
models as previously reported.25,27 The effects of the ligands 
presented here are likely to be physiologically relevant as 
endogenous LXR and FXR ligands can circulate in the plasma 
at micromolar concentrations under certain conditions and 
localized concentrations could be much higher. In a healthy 
individual, total cholesterol levels (LXR ligands) are main-
tained <4 mmol/L, but significantly higher levels have been 
reported in several conditions. Normal levels of bile acids 
(FXR ligands) in the systemic circulation are reported to be 
≥10 µmol/L in posprandial conditions, which can be further 
increased in disease.59
The data presented here are consistent with studies that 
have found that cholesterol derivatives, LXR receptor ligands, 
deregulate platelet responses to several platelet agonists34–36 
and that treatment with bile acids can cause platelet dysfunc-
tion,42 including membrane vesiculation and platelet swell-
ing.43,44 Treatment with either LXR or FXR ligands caused 
a concentration-dependent increase in phosphatidylserine 
exposure that was associated with microparticle formation 
and platelet swelling/ballooning. Increased mean platelet 
volume is a known marker of platelet hyper-reactivity and 
associated with increased risk of thrombosis. Increased mean 
platelet volume has also been observed in several pathologi-
cal conditions including hyperlipidemia, obesity, high choles-
terol, and type 2 diabetes mellitus,60–63 conditions associated 
with increased circulating levels of hydroxycholesterols and 
bile acids (LXR and FXR agonists). Our findings could, there-
fore, offer some explanation behind these observations. It is 
also interesting to note that these observations after treatment 
with GW3965 and GW4064 also provide a novel example 
of platelet ballooning and swelling that occurs independently 
of stimulation by traditional platelet agonists collagen and 
thrombin.56
Concentration-dependent increases in fibrinogen bind-
ing (that is not associated with integrin αIIbβ3 activa-
tion), α-granule protein exposure at the platelet surface and 
increased fibrin generation were also observed after treatment 
with LXR and FXR agonists, indicating the formation of a 
subset of procoagulant platelets known as coated platelets that 
are thought to be involved in supporting coagulation reactions. 
Similar to other previously described examples of increases 
in procoagulant activity and coated platelet formation, LXR 
and FXR agonist-dependent increases in procoagulant activity 
were found to be associated with, and dependent on, sustained 
intracellular calcium signaling, ROS, and loss of mitochon-
drial transmembrane potential, all of which have previously 
been described to be required for Thr/CRP-dependent coated 
platelet formation.13,19,20,64,65 Interestingly, one difference was 
observed with cyclophilin D, which was found to play a role 
in FXR agonist-mediated procoagulant platelet formation but 
was not required for LXR agonist-mediated coated platelet 
formation.
Figure 6. Generation of reactive oxygen species (ROS) is required for induction of procoagulant platelet activity by liver X receptor (LXR) 
and farnesoid X receptor (FXR) ligands. Human washed platelets were treated for 10 min with or without increasing concentrations of 
GW3965 (10 and 20 µmol/L) or GW4064 (10 and 20 µmol/L; A) in the presence of the fluorescent dye H2DCFDA (an indicator of ROS) and 
fluorescence measured. Thrombin-treated, CRP-treated, and ionomycin-treated platelets were included as positive controls. B and C, In 
the presence or absence of 10 µmol/L DPPD (n,n′-diphenyl-p-phenylenediamine), a reactive oxygen species scavenger before analysis by 
flow cytometry for (B) annexin V binding and (C) fibrinogen binding, using an antifibrinogen antibody. Results are mean+SEM for n≥3 and 
expressed as median fluorescence intensity. *P<0.05 in comparison to vehicle controls.
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Despite appearing to be hyper-reactive when in the pro-
coagulant state and able to support the assembly of coagula-
tion complexes that lead to fibrin generation, coated platelets 
have been shown to undergo closure of integrin αIIbβ3 and 
other platelet receptors,20 reducing the responsiveness of these 
platelets to platelet stimuli. Coated platelets, therefore, show a 
significant reduction in their ability to be activated by platelet 
agonists.55 Previous studies have shown that FXR and LXR 
ligands inhibit platelet aggregation to GPVI agonists and 
thrombin,25,27 and this is further supported by our observa-
tions that PAC-1 binding is reduced after treatment with either 
GW3965 or GW4064 in both CRP- and thrombin-stimulated 
platelets. It is particularly important to highlight that it is those 
platelets found to be positive for annexin V binding that show 
significantly reduced PAC-1 binding compared with vehicle 
controls, thereby suggesting that procoagulant coated platelet 
formation is associated with reduced integrin αIIbβ3 activa-
tion. Previously published data describe that agonists for both 
the LXR and FXR receptors attenuate platelet responses to 
stimulation by both GPVI agonists and thrombin and also 
inhibit stable thrombus formation after arterial laser injury in 
vivo.25,27 It has been described that during thrombus forma-
tion, 2 distinct populations of platelets appear, coaggregated 
platelets with activated αIIbβ3 integrins, which support throm-
bus growth, and loosely attached platelets that expose phos-
phatidylserine, which support coagulation but cannot support 
platelet activation.20 We hypothesize that it is this reduction in 
integrin αIIbβ3 activity observed on coated platelet formation 
after treatment with either GW3965 or GW4064 that underlies 
this inhibition of thrombus formation in vivo. We propose that 
exposure of platelets to LXR and FXR ligands convert plate-
lets to this procoagulant coated state, yet despite their abil-
ity to support coagulation, these platelets are desensitized to 
platelet stimuli through inhibition of integrin αIIbβ3, thereby 
appearing to negatively regulate platelet functional responses. 
It is also interesting to note that procoagulant platelets and 
platelets with increased platelet volume have been shown to 
be more rapidly cleared from the circulation. This could lead 
to thrombocytopenia if platelet production is not balanced 
with platelet turnover,55,66 although further study would be 
required to determine whether this is the case after prolonged 
exposure to either LXR or FXR ligands.
The work described here has significant clinical implica-
tions as circulating and localized concentrations of several 
agonists for these nuclear receptors, including cholesterol 
derivatives and bile acids, are increased under several patho-
physiological conditions. These nongenomic effects of 
nuclear receptor ligands could, therefore, contribute to plate-
let deregulation. Ligands for LXR and FXR are under clinical 
development for the treatment of diabetes mellitus, high cho-
lesterol, and obesity; and it is therefore important to balance 
their beneficial metabolic effects against their possible side 
effects on platelet reactivity and function.
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Highlights
• Treatment of platelets with liver X receptor or farnesoid X receptor ligands converts platelets to the procoagulant state and forms coated 
platelets.
• Liver X receptor and farnesoid X receptor ligand-induced coated platelets display increased phosphatidylserine exposure, platelet swelling, 
microparticle formation, increased P-selectin exposure, fibrinogen binding, and fibrin generation that is supported by increased serine protease 
activity.
• These coated platelets are, however, desensitized to platelet stimuli through receptor closure and cleavage, which is consistent with their 
ability to inhibit platelet function and stable thrombus formation in vivo.
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